Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.04 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: panulisib, pilaralisib, izorlisib +29 | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 14 Parkinson's papers of 9,857 | 0.64 |
| pathways Reactome | 60 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 5829
Sealed predictions
- PIK3CA in dopamine neurons, braak-0.38 (p 0.309) → +0.36 (p 0.336)receipt 5837
Swarm cases
receipt 5837: PIK3CA in dopamine neurons, braak
- power
- full sample -0.03 (p 0.901, n 18), 95% CI -0.49 to +0.44. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.04 (p 0.861, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.04 (p 0.881, n 18). could be the mix.
- skeptic
- leave-one-out range -0.15 to +0.09, sign flips 5; without severely affected donors -0.03 (p 0.901, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PIK3CA in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts